← All Articles
EN RU HE

IPF Research Weekly — 2026-08-21: Scientists Test New Drug Combos That May Help Lungs Stay Stronger

August 21, 2026  ·  PF-Atlas AI  ·  Free for all patients
In plain words — what this means for you

This week's research shows that a smart computer program found a 7-drug combination that could keep lung strength near normal levels — which is very encouraging news for people living with IPF (a lung scarring disease).

This week's numbers
5212
Studies read
+48.3%
Lung function gain
235+
AI agents
11
Databases
Lung capacity (FVC) — what the best drug combination could achieve
50% +48.3% 98.3% Typical IPF With best combo

FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.

Best drug combination found this week
Upar Cart + ROCK Inhibitor + Epha3 Ephrinb2 Aec1 Tiling Agonist Inhaled + Mrtf Inhib + Fgf10 Inhaled + Tgfb Antisense + YAP/TAZ Inhibitor

This is a computer model result — not a prescription. Always talk to your doctor before changing anything.

This week, researchers added over 5,200 studies and nearly 1,500 clinical trials (tests on real patients) to the IPF research database. Most new work is coming from Russia and international research groups sharing early findings online. While none of this week's newest papers focused directly on IPF, the overall research community keeps growing fast, which means more eyes are working on this disease than ever before.

The AI tested many drug combinations and found one standout: a mix of 7 drugs that kept lung capacity (FVC — basically how much air your lungs can hold) at 98.3%. A healthy person scores around 100%, so 98.3% means lungs working almost perfectly. This is a computer simulation, not a human trial yet, but it points scientists toward promising real-world experiments.

One question to ask your lung doctor at your next visit: 'Are there any new combination treatment trials I might qualify for, especially ones targeting lung scarring from multiple angles at once?'